A C18 fatty-diacid chain promotes reversible albumin binding and resistance to DPP-4 degradation, extending the plasma half-life to roughly 7 days and enabling a once-weekly dosing profile in research models
Abbasinejad, MD, board-certified in Obesity Medicine, and our team will work with you to determine the right medication and dosing schedule based on your individual health needs
I was one of the lucky ones, she says
Wegovy is GLP-1 only this explains the difference Side effects are very similar primarily gastrointestinal, worst during dose escalation Wegovy has an FDA cardiovascular benefit and now an oral tablet option Zepbound is generally cheaper at list price (~$1,086 vs ~$1,349/month) Both drop to ~$25/month with commercial insurance savings cards Neither is covered by Medicare/Medicaid for weight loss alone in 2026 The right choice depends on your health profile , insurance, and tolerance not just the weight loss numbers References Aronne LJ, et al
[DOI] [PMC free article] [PubMed] [Google Scholar] 17.Rosenstock J, et al
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)
